• Geopolitical tensions rank as the life sciences industry's top economic risk in Willis Towers Watson's Nov. 5, 2026, report.
• Restrictions could limit access to key markets, suppliers and research partners, threatening global operations.
• US drug pricing and payment reforms rank second, potentially reducing revenues, altering launch strategies and reshaping innovation funding.
• Diverging US and European regulatory approaches complicate cross-market operations, while tariff volatility disrupts manufacturing and investment planning.
• Rising healthcare costs intensify competition for public funding, shifting industry concerns from pandemic-related risks highlighted in the 2024 study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Willis Towers Watson plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050400PRIMZONEFULLFEED9870046) on November 05, 2026, and is solely responsible for the information contained therein.